RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice - PubMed (original) (raw)
. 2002 Nov 26;106(22):2827-35.
doi: 10.1161/01.cir.0000039325.03698.36.
Thoralf Wendt, Wu Qu, Yan Lu, Evanthia Lalla, Ling Ling Rong, Mouza T Goova, Bernhard Moser, Thomas Kislinger, Daniel C Lee, Yogita Kashyap, David M Stern, Ann Marie Schmidt
Affiliations
- PMID: 12451010
- DOI: 10.1161/01.cir.0000039325.03698.36
RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice
Loredana G Bucciarelli et al. Circulation. 2002.
Abstract
Background: Previous studies suggested that blockade of RAGE in diabetic apolipoprotein (apo) E-null mice suppressed early acceleration of atherosclerosis. A critical test of the potential applicability of RAGE blockade to clinical settings was its ability to impact established vascular disease. In this study, we tested the hypothesis that RAGE contributed to lesion progression in established atherosclerosis in diabetic apoE-null mice.
Methods and results: Male apoE-null mice, age 6 weeks, were rendered diabetic with streptozotocin or treated with citrate buffer. At age 14 weeks, certain mice were killed or treated with once-daily murine soluble RAGE or albumin; all mice were killed at age 20 weeks. Compared with diabetic mice at age 14 weeks, albumin-treated animals displayed increased atherosclerotic lesion area and complexity. In diabetic mice treated with sRAGE from age 14 to 20 weeks, lesion area and complexity were significantly reduced and not statistically different from those observed in diabetic mice at age 14 weeks. In parallel, decreased parameters of inflammation and mononuclear phagocyte and smooth muscle cell activation were observed.
Conclusions: RAGE contributes not only to accelerated lesion formation in diabetic apoE-null mice but also to lesion progression. Blockade of RAGE may be a novel strategy to stabilize atherosclerosis and vascular inflammation in established diabetes.
Comment in
- Diabetic macrovascular disease: the glucose paradox?
Libby P, Plutzky J. Libby P, et al. Circulation. 2002 Nov 26;106(22):2760-3. doi: 10.1161/01.cir.0000037282.92395.ae. Circulation. 2002. PMID: 12450998 No abstract available.
Similar articles
- Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice.
Bu DX, Rai V, Shen X, Rosario R, Lu Y, D'Agati V, Yan SF, Friedman RA, Nuglozeh E, Schmidt AM. Bu DX, et al. Circ Res. 2010 Apr 2;106(6):1040-51. doi: 10.1161/CIRCRESAHA.109.201103. Epub 2010 Feb 4. Circ Res. 2010. PMID: 20133903 Free PMC article. - RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes.
Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF. Wendt T, et al. Atherosclerosis. 2006 Mar;185(1):70-7. doi: 10.1016/j.atherosclerosis.2005.06.013. Epub 2005 Aug 1. Atherosclerosis. 2006. PMID: 16076470 - Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice.
Lewis P, Stefanovic N, Pete J, Calkin AC, Giunti S, Thallas-Bonke V, Jandeleit-Dahm KA, Allen TJ, Kola I, Cooper ME, de Haan JB. Lewis P, et al. Circulation. 2007 Apr 24;115(16):2178-87. doi: 10.1161/CIRCULATIONAHA.106.664250. Epub 2007 Apr 9. Circulation. 2007. PMID: 17420349 - RAGE axis: Animal models and novel insights into the vascular complications of diabetes.
Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, Yan SF, Schmidt AM. Naka Y, et al. Arterioscler Thromb Vasc Biol. 2004 Aug;24(8):1342-9. doi: 10.1161/01.ATV.0000133191.71196.90. Epub 2004 May 20. Arterioscler Thromb Vasc Biol. 2004. PMID: 15155381 Review. - Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
Schmidt AM, Yan SD, Wautier JL, Stern D. Schmidt AM, et al. Circ Res. 1999 Mar 19;84(5):489-97. doi: 10.1161/01.res.84.5.489. Circ Res. 1999. PMID: 10082470 Review.
Cited by
- ERK and Akt signaling pathways are involved in advanced glycation end product-induced autophagy in rat vascular smooth muscle cells.
Hu P, Lai D, Lu P, Gao J, He H. Hu P, et al. Int J Mol Med. 2012 Apr;29(4):613-8. doi: 10.3892/ijmm.2012.891. Epub 2012 Jan 23. Int J Mol Med. 2012. PMID: 22293957 Free PMC article. - RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases.
Koyama H, Yamamoto H, Nishizawa Y. Koyama H, et al. Mol Med. 2007 Nov-Dec;13(11-12):625-35. doi: 10.2119/2007-00087.Koyama. Mol Med. 2007. PMID: 17932553 Free PMC article. Review. - Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.
Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Yoshida T, Imaizumi T. Nakamura K, et al. Mol Med. 2007 Mar-Apr;13(3-4):185-9. doi: 10.2119/2006–00090.Nakamura. Mol Med. 2007. PMID: 17592553 Free PMC article. - Dendritic cell-mediated chronic low-grade inflammation is regulated by the RAGE-TLR4-PKCβ1 signaling pathway in diabetic atherosclerosis.
Zhao L, Li Y, Xu T, Lv Q, Bi X, Liu X, Fu G, Zou Y, Ge J, Chen Z, Zhang W. Zhao L, et al. Mol Med. 2022 Jan 21;28(1):4. doi: 10.1186/s10020-022-00431-6. Mol Med. 2022. PMID: 35062863 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous